04.11.12
SkyePharma has signed a second agreement to conduct a feasibility study with RespiVert Ltd., a Janssen Biotech company. The agreement is for a feasibility study to develop a dry powder inhaler (DPI) dosage form for a RespiVert compound and follows the successful completion of a similar program on another RespiVert compound. Both projects are aimed at developing new therapeutic options for patients living with severe, chronic respiratory diseases including chronic obstructive pulmonary disease (COPD) and severe asthma.
SkyePharma’s chief executive officer, Peter Grant, said, “We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases. Over the past 20 years, SkyePharma has established world-class respiratory development expertise covering both metered dose and dry powder inhalation products.”
SkyePharma’s chief executive officer, Peter Grant, said, “We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases. Over the past 20 years, SkyePharma has established world-class respiratory development expertise covering both metered dose and dry powder inhalation products.”